APREA THERAPEUTICS INC (APRE)

Company Profile

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. The company is headquartered in Doylestown, Pennsylvania and currently employs 9 full-time employees. The company went IPO on 2019-10-03. The company is focused on developing novel synthetic lethality-based cancer therapeutics that target DNA damage response (DDR) pathways. Its synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DDR. The company is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Its lead WEE1 inhibitor product candidate is ATRN-1051. In addition, it has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. The company is also evaluating combination opportunities within its pipeline, including research on the combination of ATRN-119 and ATRN-1051. Its pipeline includes the clinical-stage asset ATRN-119, an ATR inhibitor that is being evaluated in a Phase 1/2a clinical trial in patients with advanced solid tumors having mutations in defined DDR-related genes.

Company Info

APREA THERAPEUTICS INC

3805 OLD EASTON ROAD

Doylestown PENNSYLVANIA 02116

P: 16174639385

CEO: Christian S. Schade

Employees: 9

Website: https://www.aprea.com/